Identification of the principal proteoglycan-binding site in LDL: A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding

Journal of Clinical Investigation

Volumn 101, Issue 12, 1998, Pages 2658-2664

  Borén, Jan ^a,d   Olin, Katherine ^c   Lee, Isabelle ^a   Chait, Alan ^c   Wight, Thomas N ^c   Innerarity, Thomas L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

apo B; Atherosclerosis; Lipoproteins; Proteoglycans; Transgenic mice

Indexed keywords

APOLIPOPROTEIN B100; GLUTAMIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MUTANT PROTEIN; PROTEOGLYCAN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHEMICAL MODIFICATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RISK FACTOR;

EID: 0032526201     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI2265     Document Type: Article

References (44)

1. Ross, R. 1995. Cell biology of atherosclerosis. Annu. Rev. Physiol. 57: 791-804.
2. Hurt-Camejo, E., U. Olsson, O. Wiklund, G. Bondjers, and G. Camejo. 1997. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17:1011-1017.
3. Williams, K.J., and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15:551-561.
4. Radhakrishnamurthy, B., S.R. Srinivasan, P. Vijayagopal, and G.S. Berenson. 1990. Arterial wall proteoglycans - biological properties related to pathogenesis of atherosclerosis. Eur. Heart J. 11 (Suppl. E):148-157.
5. Schönherr, E., H.T. Järveläinen, L.J. Sandell, and T.N. Wight. 1991. Effects of platelet-derived growth factor and transforming growth factor-β1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J. Biol. Chem. 266:17640-17647.
6. 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler. Thromb. 13:1026-1036.
7. Mahley, R.W., K.H. Weisgraber, and T.L. Innerarity. 1979. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim. Biophys. Acta. 575:81-91.
8. Camejo, G., S.-O. Olofsson, F. Lopez, P. Carlsson, and G. Bondjers. 1988. Identification of apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans. Arteriosclerosis. 8:368-377.
9. Weisgraber, K.H., and S.C. Rall, Jr. 1987. Human apolipoprotein B-100 heparin-binding sites. J. Biol. Chem. 262:11097-11103.
10. Hirose, N., D.T. Blankenship, M.A. Krivanek, R.L. Jackson, and A.D. Cardin. 1987. Isolation and characterization of four heparin-binding cyanogen bromide peptides of human plasma apolipoprotein B. Biochemistry. 26:5505-5512.
11. Olsson, U., G. Camejo, E. Hurt-Camejo, K. Elfsber, O. Wiklund, and G. Bondjers. 1997. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor. Arterioscler. Thromb. Vasc. Biol. 17:149-155.
12. Weisgraber, K.H., S.C. Rall, Jr., R.W. Mahley, R.W. Milne, Y.L. Marcel, and J.T. Sparrow. 1986. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J. Biol. Chem. 261:2068-2076.
13. Borén, J., I. Lee, M.J. Callow, E.M. Rubin, and T.L. Innerarity. 1996. A simple and efficient method for making site-directed mutants, deletions, and fusions of large DNA such as P1 and BAC clones. Genome Res. 6:1123-1130.
14. Borén, J., I. Lee, W. Zhu, K. Arnold, S. Taylor, and T.L. Innerarity. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J. Clin. Invest. 101:1084-1093.
15. Linton, M.F., R.V. Farese, Jr., G. Chiesa, D.S. Grass, P. Chin, R.E. Hammer, H.H. Hobbs, and S.G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92:3029-3037.
16. Yao, Z., B.D. Blackhart, D.F. Johnson, S.M. Taylor, K.W. Haubold, and B.J. McCarthy. 1992. Elimination of apolipoprotein B48 formation in rat hepatoma cell lines transfected with mutant human apolipoprotein B cDNA constructs. J. Biol. Chem. 267:1175-1182.
17. Milne, R.W., R. Theolis, Jr., R.B. Verdery, and Y.L. Marcel. 1983. Characterization of monoclonal antibodies against human low density lipoprotein. Arteriosclerosis. 3:23-30.
18. Basu, S.K., J.L. Goldstein, R.G.W. Anderson, and M.S. Brown. 1976. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc. Natl. Acad. Sci. USA. 73:3178-3182.
19. Mahley, R.W., T.L. Innerarity, R.E. Pitas, K.H. Weisgraber, J.H. Brown, and E. Gross. 1977. Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins. J. Biol. Chem. 252:7279-7287.
20. Arnold, K.S., T.L. Innerarity, R.E. Pitas, and R.W. Mahley. 1992. Lipoprotein-receptor interactions. In Lipoprotein Analysis. A Practical Approach. C.A. Converse and E.R. Skinner, editors. Oxford University Press, Oxford. 145-168.
21. Chang, Y., M. Yanagishita, V.C. Hascall, and T.N. Wight. 1983. Proteoglycans synthesized by smooth muscle cells derived from monkey (Macaca nemestrina) aorta. J. Biol. Chem. 258:5679-5688.
22. Camejo, G., G. Fager, B. Rosengren, E. Hurt-Camejo, and G. Bondjers. 1993. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J. Biol. Chem. 268: 14131-14137.
23. Goldstein, J.L., S.K. Basu, G.Y. Brunschede, and M.S. Brown. 1976. Release of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell. 7:85-95.
24. Ji, Z.-S., S. Fazio, and R.W. Mahley. 1994. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J. Biol. Chem. 269:13421-13428.
25. Jackson, R.L., S.J. Busch, and A.D. Cardin. 1991. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol. Rev. 71:481-539.
26. McCormick, S.P.A., J.K. Ng, M. Véniant, J. Borén, V. Pierotti, L.M. Flynn, D.S. Grass, A. Connolly, and S.G. Young. 1996. Transgenic mice that overexpress mouse apolipoprotein B. Evidence that the DNA sequences controlling intestinal expression of the apolipoprotein B gene are distant from the structural gene. J. Biol. Chem. 271:11963-11970.
27. Ludwig, E.H., P.N. Hopkins, A. Allen, L.L. Wu, R.R. Williams, J.L. Anderson, R.H. Ward, J.-M. Lalouel, and T.L. Innerarity. 1997. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J. Lipid Res. 38: 1361-1373.
28. Dunning, A.M., R. Houlston, J. Frostegård, J. Revill, J. Nilsson, A. Hamsten, P. Talmud, and S. Humphries. 1991. Genetic evidence that the putative receptor binding domain of apolipoprotein B (residues 3130 to 3630) is not the only region of the protein involved in interaction with the low density lipoprotein receptor. Biochim. Biophys. Acta. 1096:231-237.
29. Weisgraber, K.H., T.L. Innerarity, and R.W. Mahley. 1978. Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J. Biol. Chem. 253:9053-9062.
30. Paananen, K., and P.T. Knvanen. 1994. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules. J. Biol. Chem. 269:2023-2031.
31. Tabas, I., Y. Li, R.W. Brocia, S.W. Xu, T.L. Swenson, and K.J. Williams. 1993. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J. Biol. Chem. 268:20419-20432.
32. Cardin, A.D., C.J. Randall, N. Hirose, and R.L. Jackson. 1987. Physical-chemical interaction of heparin and human plasma low-density lipoproteins. Biochemistry. 26:5513-5518.
33. Hurt, E., and G. Camejo. 1987. Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis. 67:115-126.
34. Cardoso, L.E.M., and P.A.S. Mourão. 1994. Glycosaminoglycan fractions from human arteries presenting diverse susceptibilities to atherosclerosis have different binding affinities to plasma LDL. Arterioscler. Thromb. 14:115-124.
35. Ismail, N.A.E., M.Z. Alavi, and S. Moore. 1994. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells. Atherosclerosis. 105:79-87.
36. Lindén, T., G. Bondjers, G. Camejo, R. Bergstrand, L. Wilhelmsen, and O. Wiklund. 1989. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur. J. Clin. Invest. 19:38-44.
37. Camejo, G., E. Hurt-Camejo, U. Olsson, and G. Bondjers. 1993. Proteoglycans and lipoproteins in atherosclerosis. Curr. Op. Lipidol. 4:385-391.
38. Camejo, G., B. Rosengren, U. Olson, F. Lopez, S.-O. Olofson, C. Westerlund, and G. Bondjers. 1990. Molecular basis of the association of arterial proteoglycans with low density lipoproteins: Its effect on the structure of the lipoprotein particle. Eur. Heart J. 11 (Suppl. E):164-173.
39. Walton, K.W., and N. Williamson. 1968. Histological and immunofluorescent studies on the evolution of the human atheromatous plaque. J. Atheroscler. Res. 8:599-624.
40. Hoff, H.F., and M.G. Bond. 1983. Apolipoprotein B localization in coronary atherosclerotic plaques from cynomolgus monkeys. Artery. 12:104-116.
41. Hoff, H.F., and W.D. Wagner. 1986. Plasma low density lipoprotein accumulation in aortas of hypercholesterolemic swine correlates with modifications in aortic glycosaminoglycan composition. Atherosclerosis. 61:231-236.
42. Nievelstein-Post, P., G. Mottino, A. Fogelman, and J. Frank. 1994. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler. Thromb. 14:1151-1161.
43. Galis, Z.S., M.Z. Alavi, and S. Moore. 1993. Co-localization of aortic apolipoprotein B and chondroitin sulfate in an injury model of atherosclerosis. Am. J. Pathol. 142:1432-1438.
44. Véniant, M.M., V. Pierotti, D. Newland, C.M. Cham, D.A. Sanan, R.L. Walzem, and S.G. Young. 1997. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J. Clin. Invest. 100:180-188.